Pulse Biosciences, Inc 8-K, filed Jun 7, 2024
Pulse Biosciences, Inc. (PLSE)
8-K
2024-06-07
For: 2024-06-06
View Original
Added on
April 10, 2026
About this 8-K
Pulse Biosciences, Inc filed this 8-K on June 7, 2024, reporting on events of June 6, 2024.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 6, 2024
|
|
||
|
(Exact Name of Registrant as Specified in Its Charter)
|
||
|
|
|
|
|
(State or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
|
||
|
(Address of Principal Executive Offices) (Zip Code)
|
||
| (Registrant’s Telephone Number, Including Area Code) | ||
|
Not Applicable
|
|
(Former Name or Former Address, If Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
|
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.02
|
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
|
On June 6, 2024, the Company held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). Director Shelley D. Spray did not stand for reelection at the Annual Meeting. The decision not to stand for reelection was not attributable to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
|
Item 5.07
|
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
|
On June 6, 2024, the Company held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting was a virtual meeting held via live audio webcast. The stockholders of the Company voted on the following items at the Annual Meeting:
| 1. | to elect five directors to hold office until the Company’s 2025 annual meeting and until their successors are duly elected and qualified, subject to their earlier resignation or removal; and | |
| 2. | to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. |
The voting results for each of these proposals are detailed below:
| 1. | Election of Directors |
| Nominee | For | Against | Abstained | Broker Non-Votes |
| Robert W. Duggan | 39,524,541 | 1,235,315 | 412 | 9,270,519 |
| Manmeet S. Soni | 39,906,625 | 851,090 | 2,553 | 9,270,519 |
| Darrin R. Uecker | 40,303,460 | 452,611 | 4,197 | 9,270,519 |
| Richard A. van den Broek | 40,288,000 | 467,041 | 5,227 | 9,270,519 |
| Mahkam Zanganeh, D.D.S. | 40,692,426 | 62,869 | 4,973 | 9,270,519 |
Each director nominee was duly elected to serve until the Company’s 2025 Annual Meeting and until his or her successor is duly elected and qualified.
| 2. | Ratification of Appointment of Independent Registered Public Accounting Firm |
| For | Against | Abstained | Broker Non-Votes |
| 50,006,220 | 5,763 | 18,804 | N/A |
The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
PULSE BIOSCIENCES, INC.
|
|||
|
Date: June 7, 2024
|
By:
|
/s/ Burke T. Barrett
|
|
| Burke T. Barrett | |||
|
President and Chief Executive Officer
(Principal Executive and Principal Financial Officer) |
|||